Skip to main content

#160724

Caki-2 SETD2 KO cell line

Cat. #160724

Caki-2 SETD2 KO cell line

Cat. #: 160724

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 10-12 weeks

Organism: Human

Tissue: Kidney

Model: Knock-Out

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Sergio F de Almeida

Institute: Instituto de Medicina Molecular Jo?„ƒo Lobo Antunes

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Caki-2 SETD2 KO cell line
  • Alternate name: HBP231, HIF-1, HIP-1, HYPB, KMT3A
  • Research fields: Cancer;Genetics
  • Tool sub type: Continuous
  • Parental cell: Clear cell renal cell carcinoma cell line (Caki-2)
  • Organism: Human
  • Tissue: Kidney
  • Model: Knock-Out
  • Conditional: No
  • Description: Experimental ablation of SETD2 gene expression using the CRISPR/Cas9 system renders Caki-2-SETD2 knockout cells a valuable tool to investigate the role of H3K36me3 histone methylation in processes such as transcription or DNA repair.
  • Production details: CRISPR/Cas9 KO
  • Additional notes: Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Ca...
  • Recommended controls: Caki-2 Parental Line

Target Details

  • Target: SET domain containing 2

Applications

  • Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

  • Format: Frozen
  • Growth medium: Grow as monolayers in Dulbecco's modified Eagle medium, supplemented with 10% (v/v) FBS, 1% (v/v) nonessential amino acids, 1% (v/v) L-glutamine and 100U/mL penicillin-streptomycin, at 37?‚°C in a humidified atmosphere with 5% CO2.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

Related Tools

  • Related tools: Caki-2 DNMT3A KO cell line

References

  • de Matos et al. 2019. Cancers (Basel). 11(3):. PMID: 30897760.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.